-
Company Insights
New![]()
Innovation and Patenting activity of Oramed Pharmaceuticals Inc Q3 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Oramed Pharmaceuticals Inc Q3 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
New![]()
Net Present Value Model: Oramed Pharmaceuticals Inc’s Insulin Human
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Insulin Human in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Insulin Human in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drug Details: Insulin human (ORMD-0801) is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Insulin Human in Type 1 Diabetes (Juvenile Diabetes)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Insulin Human in Type 1 Diabetes (Juvenile Diabetes) Drug Details: Insulin human (ORMD-0801) is under...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Insulin human in Non-Alcoholic Steatohepatitis (NASH)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Insulin human in Non-Alcoholic Steatohepatitis (NASH)Drug Details:Insulin human (ORMD-0801) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BRII-693 in Pseudomonas aeruginosa Infections
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BRII-693 in Pseudomonas aeruginosa Infections Drug Details: BRII-693 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MAX-4 in Refractory Acute Myeloid Leukemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. MAX-4 in Refractory Acute Myeloid Leukemia Drug Details: MAX-4 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – 6MW-3211 in Myelodysplastic Syndrome
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. 6MW-3211 in Myelodysplastic Syndrome Drug Details: 6MW-3211 is under development for the treatment of advanced...
-
Product Insights
![]()
Orams Marine/ Panuku Dev – Wynyard Quarter Marine Facility – Auckland
Equip yourself with the essential tools needed to make informed and profitable decisions with our Orams Marine/ Panuku Dev - Wynyard Quarter Marine Facility - Auckland report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive...
-
Company Profile
![]()
Oramed Pharmaceuticals Inc – Company Profile
Oramed Pharmaceuticals Inc (Oramed) is a pre-clinical pharmaceutical company that carries out research and development of novel pharmaceutical solutions, comprising an oral insulin capsule used for the treatment of people with diabetes and orally ingestible capsules for delivery of other polypeptides. It developed a novel proprietary platform technology, protein oral delivery (POD) to transform injectable treatments into oral therapies. The technology allows for the oral delivery of drugs and is administered only by injection. Its pipeline products are intended for...
Add to Basket
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.